君赛生物亮相2026亚洲金融论坛

Group 1 - The 19th Asian Financial Forum, co-hosted by the Hong Kong SAR government and the Hong Kong Trade Development Council, introduced the "Global Industry Summit" focusing on high-growth and high-value sectors such as biomedicine and healthcare [1] - Junshi Biosciences, a key exhibitor in the biomedicine sector, showcased its technological breakthroughs, product pipeline, and commercialization prospects in the TIL (tumor-infiltrating lymphocyte) therapy field [1] - The company submitted its listing application to the Hong Kong Stock Exchange in December last year and has completed multiple financing rounds totaling nearly 800 million RMB, with a recent C round completed in November 2025, achieving a valuation of 2.137 billion RMB [1] Group 2 - Junshi Biosciences' core product, GC101, is the world's first natural TIL cell new drug that does not require high-intensity lymphodepletion chemotherapy or IL-2 administration, providing long-term benefits to patients with advanced metastatic solid tumors [2] - The product has shown complete tumor clearance in multiple patients, with the longest progression-free survival exceeding 4 years [2] - The company is also actively developing the world's first in-vivo TIL therapy, aiming to shift TIL therapy from a "highly personalized" to a "quasi-off-the-shelf" model, significantly reducing production costs and patient wait times, thereby enhancing accessibility [2]